Seasonal Variation in Lipids in Patients Following Acute Coronary Syndrome on Fixed Doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study) - 13/08/11
, Christopher P. Cannon, MD a, b, Sabina A. Murphy, MPH a, b, Carolyn H. McCabe, BS a, b, C. Michael Gibson, MD, MS a, b
Corresponding author: Tel: 617-278-0145; fax: 617-975-0955Résumé |
Previous studies have shown seasonal variation in lipids. To understand whether this variation exists in patients with acute coronary syndromes receiving statins, we examined data from the PROVE IT-TIMI 22 Study. At baseline, no significant difference in low-density lipoprotein (LDL) cholesterol was observed when stratified by season. However, a statistically significant difference in high-density lipoprotein cholesterol between winter (37 mg/dl) and summer (39 mg/dl) was observed (p <0.001) at baseline. On treatment, median LDL cholesterol was 102 mg/dl in winter versus 96 mg/dl in summer (p <0.001) for the pravastatin group and 68 mg/dl in winter versus 62 mg/dl in summer (p <0.001) for the atorvastatin group. Median high-density lipoprotein cholesterol was 43 mg/dl in summer versus 41 mg/dl in winter in the pravastatin group and 42 mg/dl in summer versus 39 mg/dl in winter in the atorvastatin group (p <0.001). More patients achieved LDL cholesterol <100 mg/dl in summer at 56% versus 47% in winter in the pravastatin group (p <0.001) and 89% versus 87% in winter for the atorvastatin group (p = 0.11). Achievement of LDL cholesterol <70 mg/dl was also higher in summer than winter. In conclusion, this was the first evidence of seasonal variability in cholesterol in patients with acute coronary syndromes treated with statins. This variability affected achievement of National Cholesterol Education Program goals and may affect management decisions based on season of collection.
Le texte complet de cet article est disponible en PDF.Plan
| The PROVE IT-TIMI 22 Study was supported by a research grant from Bristol-Myers Squibb, New York, New York. Dr. Wiviott has received honoraria for speaking from Pfizer, New York, New York, and Merck and Co., Whitehouse Station, New Jersey, and consulting fees from Sanofi-Aventis, Bridgewater, New Jersey. Dr. Cannon currently receives research grants/support from Accumetrics, San Diego, California, AstraZeneca, Wilmington, Delaware, Bristol-Myers Squibb/Sanofi Partnership, New York, New York, Glaxo Smith Kline Brentford, Middlesex, United Kingdom, and Merck/Schering Plough Partnership, Kenilworth, New Jersey. |
Vol 103 - N° 8
P. 1056-1060 - avril 2009 Retour au numéro
Article précédent
- Door-to-Balloon Times in Hospitals Within the Get-With-The-Guidelines Registry After Initiation of the Door-to-Balloon (D2B) Alliance
- Brahmajee K. Nallamothu, Harlan M. Krumholz, Eric D. Peterson, Wenqin Pan, Elizabeth Bradley, Amy F. Stern, Frederick A. Masoudi, David M. Janicke, Adrian F. Hernandez, Christopher P. Cannon, Gregg C. Fonarow, D2B Alliance and the American Heart Association Get-With-The-Guidelines Investigators
- Troponin I Rise After Pacemaker Implantation at the Time of “Universal Definition of Myocardial Infarction”
- Cristian Martignani, Igor Diemberger, Mauro Biffi, Matteo Ziacchi, Davide Saporito, Cinzia Valzania, Matteo Bertini, Giulia Domenichini, Angelo Branzi, Giuseppe Boriani
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?